Your browser doesn't support javascript.
Impact of the COVID-19 Pandemic on Healthcare Resource Utilization in Individuals with Major Depressive Disorder.
Liberman, Joshua N; Bhattacharjee, Sandipan; Rui, Pinyao; Ruetsch, Charles; Rothman, Brian; Kulkarni, Amit; Forma, Felicia.
  • Liberman JN; Health Analytics, LLC, USA.
  • Bhattacharjee S; Otsuka Pharmaceutical Development & Commercialization, Inc, USA.
  • Rui P; Health Analytics, LLC, USA.
  • Ruetsch C; Health Analytics, LLC, USA.
  • Rothman B; Otsuka Pharmaceutical Development & Commercialization, Inc, USA.
  • Kulkarni A; Otsuka Pharmaceutical Development & Commercialization, Inc, USA.
  • Forma F; Former employee of Otsuka Pharmaceutical Development & Commercialization, Inc.
Health Serv Res Manag Epidemiol ; 9: 23333928221111864, 2022.
Article in English | MEDLINE | ID: covidwho-1928060
ABSTRACT

Objective:

To estimate the impact COVID-19 pandemic on healthcare resource utilization (HCRU) among individuals with major depressive disorder (MDD).

Method:

A retrospective cohort study was conducted to compare HCRU in the twelve months prior to and six months following pandemic onset among 1,318,709 individuals with MDD and propensity-score matched controls. Outcomes were monthly rates of all-cause and MDD-specific outpatient, inpatient, and prescription medication HCRU. Piecewise random effects models were used to adjust for patient-level clustering, trends over time, and pre-pandemic factors.

Results:

In the first month following onset, outpatient HCRU declined with primary care visits down 25.1%. Following this initial decline, outpatient HCRU increased, exceeding pre-pandemic rates within three months. By April 2020, three quarters of all psychotherapy sessions were delivered by telehealth, followed by psychiatry (62.3%), and primary care visits (30.1%). The use of telehealth remained highest for psychotherapy and psychiatry (representing 67.6% and 54.2% of visits, respectively, in September 2020). All-cause partial-day hospitalizations declined 50.5% and remained depressed through July 2020 (down 18.3%). Beginning in the first month post-onset, prescription medication HCRU increased for all antidepressant and antipsychotic medication classes serotonin modulators ( + 11.8%), bupropion ( + 10.4%), SSRIs ( + 9.0%), SNRIs ( + 8.6%), and atypical antipsychotics ( + 7.5%).

Conclusions:

Following pandemic onset, individuals with MDD realized an immediate, but short-lived, reduction in primary care HCRU. Telehealth use remained elevated through the first six months. The most significant and sustained reduction in HCRU was noted for partial-day hospitalizations and all-cause ED visits.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Language: English Journal: Health Serv Res Manag Epidemiol Year: 2022 Document Type: Article Affiliation country: 23333928221111864

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Language: English Journal: Health Serv Res Manag Epidemiol Year: 2022 Document Type: Article Affiliation country: 23333928221111864